Perspective Therapeutics ... (CATX)
AI Score
Our AI model analyzes fundamental, technical, and statistical indicators
to predict the probability of a bullish trend over the next three months.
We regularly update and refine our models to deliver the most reliable forecasts
for you.
Bullish Probability | Sentiment | Score |
---|---|---|
+80% | Strong Buy | 10 |
+75% | Buy | 9 |
+70% | Buy | 8 |
+60% | Buy | 7 |
+50% | Hold | 6 |
+45% | Hold | 5 |
+40% | Hold | 4 |
+35% | Sell | 3 |
+30% | Sell | 2 |
+20% | Strong Sell | 1 |
Company Description
Perspective Therapeutics, Inc., together with its subsidiaries, develops, manufactures, sells, and markets isotope-based medical products and devices for the treatment of cancer and other malignant diseases in the United States and internationally.
The company offers CS-1 Cesium-131 brachytherapy seeds for the treatment of prostate, brain, lung, head and neck, gynecological, pelvic/abdominal, and colorectal cancers.
It sells its products to facilities or physician practices that utilize various surgical facilities.
The company was formerly known as Isoray, Inc. and changed its name to Perspective Therapeutics, Inc. in February 2022.
Perspective Therapeutics, Inc. was founded in 1998 and is based in Richland, Washington.
Country | United States |
IPO Date | Nov 10, 2005 |
Industry | Medical - Devices |
Sector | Healthcare |
Employees | 116 |
CEO | Johan M. Spoor |
Contact Details
Address: 350 Hills Street Richland, Washington United States | |
Website | https://www.perspectivetherapeutics.com |
Stock Details
Ticker Symbol | CATX |
Exchange | AMEX |
Fiscal Year | July - June |
Reporting Currency | USD |
CIK Code | 0000728387 |
CUSIP Number | n/a |
ISIN Number | US46489V1044 |
Employer ID | 41-1458152 |
SIC Code | 3841 |
Key Executives
Name | Position |
---|---|
Johan M. Spoor | Chief Executive Officer & Director |
Juan Graham | Chief Financial Officer |
Amos Hedt BA, PGradDip | Chief Business Strategy Officer |
Andrew Bright | Executive Vice President of Brachytherapy |
Annie J. Cheng | Vice President of Investor Relations |
Dr. Frances L. Johnson M.D. | Chief Innovation Officer |
Dr. Markus Puhlmann M.B.A., M.D. | Chief Medical Officer |
Dr. Michael K. Schultz Ph.D. | Chief Science Officer |
Jonathan R. Hunt | Chief Accounting Officer |
Shane Cobb | Executive Vice President of Operations |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Jan 24, 2025 | 8-K | Current Report |
Jan 13, 2025 | 8-K | Current Report |
Jan 07, 2025 | 4 | Filing |
Jan 07, 2025 | 3 | Filing |
Jan 06, 2025 | 8-K | Current Report |
Dec 06, 2024 | 4 | Filing |
Dec 04, 2024 | 4 | Filing |
Dec 04, 2024 | 4/A | [Amend] Filing |
Dec 04, 2024 | 4/A | [Amend] Filing |
Dec 04, 2024 | 8-K | Current Report |